Wednesday, January 25, 2023 OV25: A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations (STICs and STONEs) has been closed to accrual. 117 of the planned 414 patients were randomized (80 from Canada and 37 from Australia). The study was looking to see if taking Acetylsalicylic Acid (ASA), commonly known as aspirin, every day can reduce the risk of ovarian cancer in women who are at high risk and have been identified as having the BRCA1 or BRCA2 genetic mutation. Due to the presence of the BRCA1 or BRCA2 genetic mutation, women have an increased risk of getting ovarian cancer and are often offered surgery to reduce the possibility of the occurrence of cancer. This surgery involves taking out the fallopian tubes and ovaries. This study will look at tissue samples from fallopian tubes and ovaries that have been removed during preventative surgery. For more information please visit the OV25 members trial page IND237: A Phase II Study of CFI-400945 in Patients with Advanced/Metastatic Breast Cancer has been closed to accrual. The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of the disease and relieve some symptoms of cancer. Patients will have already had at least one chemotherapy treatment for their disease at this stage. CFI-400945 is a new type of drug for breast cancer. Laboratory tests show that it works by blocking a specific protein called Polo-like Kinase 4 (PLK4) that is involved in cancer cell growth. CFI-400945 may slow down the growth of cancer cells or may cause cancer cells to die. This drug has been shown to shrink tumours in animals and has been studied in some patients and appears well tolerated with little side effects. CFI-400945 seems promising but it is not clear if it can offer better results than standard therapy.
